Meeting
2018 Gastrointestinal Cancers Symposium
The relationship between dose to skeletal muscle area ratio and gemcitabine nab-paclitaxel toxicity in pancreatic ductal adenocarcinoma.
Authors
Rachel Wong
Eastern Health Clinical School, Monash University, Melbourne, Australia
Rachel Wong , Julia Freckelton , Daniel Croagh , Darcy Quinn Holt , Adrian Fox , Margaret Lee , Gregory Thomas Moore
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 492)
DOI
10.1200/JCO.2018.36.4_suppl.492
Abstract #
492
Poster Bd #
N16
Abstract Disclosures
Similar Posters
First Author: Evan Justin Walker
Poster
2021 ASCO Annual Meeting
Alternating gemcitabine/nab-paclitaxel (GA) and 5-FU/leucovorin/irinotecan (FOLFIRI) as first-line treatment for de novo metastatic pancreatic cancer (MPC): Safety and effect.
First Author: Brett A. Schroeder
Poster
2018 Gastrointestinal Cancers Symposium
Efficacy of nab-paclitaxel plus gemcitabine (AG) vs. FOLFIRINOX as first line chemotherapy for metastatic pancreatic cancer (mPC): Real world experiences.
First Author: Inhwang Hwang
Poster
2017 Gastrointestinal Cancers Symposium
Clinical outcome of modified FOLFIRINOX versus Gemcitabine plus nab-paclitaxel as first line chemotherapy in metastatic pancreatic cancer.
First Author: Kazuo Watanabe